Breaking News, Promotions & Moves

CalciMedica Appoints Chief Financial Officer

Stephen Bardin brings extensive capital raising, corporate development, and strategic finance expertise to the role.

Author Image

By: Charlie Sternberg

Associate Editor

CalciMedica Inc., a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, has appointed Stephen Bardin as Chief Financial Officer. Meanwhile, Daniel Geffken, Interim Chief Financial Officer, will depart the company upon filing the company’s third-quarter financial statements.   Bardin brings extensive capital raising, corporate development, an...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters